Brief: SynAct Pharma Q1 Adj. Loss per Share at EPS SEK 1.59
05/05/2023 06:12
May 5 (Reuters) - SynAct Pharma Q1 cash flow from operating activities SEK -30.472 million. * Q1 net income SEK -49.878 million * Q1 sales SEK 0 * Q1 operating expenses SEK 58.248 million * Q1 adjusted EPS SEK -1.59
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026